Big Data and Adverse Drug Reaction Detection

R Harpaz; W DuMochel; N H Shah

doi:10.1002/cpt.302

Big Data and Adverse Drug Reaction Detection

Clin Pharmacol Ther. 2016 Mar;99(3):268-70. doi: 10.1002/cpt.302. Epub 2015 Dec 23.

Authors

R Harpaz¹, W DuMochel¹, N H Shah²

Affiliations

¹ Oracle Health Sciences, Bedford, Massachusetts, USA.
² Stanford University, Stanford, California, USA.

PMID: 26575203
DOI: 10.1002/cpt.302

Abstract

Big Data holds the promise of fundamentally transforming the manner in which adverse drug reactions can be identified and evaluated. This commentary discusses new data sources that are envisioned to form a Big Data-enabled pharmacovigilance system and the role of these data in powering the future of adverse drug reactions detection.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Adverse Drug Reaction Reporting Systems / statistics & numerical data*
Databases, Factual*
Humans
Pharmacovigilance*

Grants and funding

R01 GM101430/GM/NIGMS NIH HHS/United States